ZIRGAN contains the active ingredient ganciclovir, which is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses (HSV).1
Ganciclovir is transformed by viral and cellular thymidine kinases to ganciclovir triphosphate, which works as an antiviral agent by inhibiting the synthesis of viral DNA in 2 ways1:
In uninfected cells, cellular thymidine kinase is unable to substantially phosphorylate the ganciclovir prodrug, and cellular DNA polymerase is less sensitive to ganciclovir inhibition. This contributes to the relative lack of ganciclovir cytotoxicity in healthy cells.2
Gel formulation allows for increased exposure of
ZIRGAN at the site of action on the ocular surface.3
Please see Important Safety Information below.
See if your patients are covered with Bausch + Lomb’s formulary tool.
Get dosing and handling information about ZIRGAN.
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
References: 1. ZIRGAN [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2016. 2. St. Clair MH, Lambe CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother. 1987;31(6):844-849. 3. Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014;10:665-681.
Please choose an option below: